trending Market Intelligence /marketintelligence/en/news-insights/trending/pu05os-anwsd0yl-fxpabg2 content esgSubNav
In This List

Novocure makes board changes

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novocure makes board changes

NovoCure Ltd. appointed David Hung and Sherilyn McCoy to its board.

Hung is the former president and CEO of Medivation Inc., a privately held biopharmaceutical company. McCoy is the former CEO of Avon Products Inc. which sells beauty, household and personal care items.

"Both will provide important insights and guidance as we grow our glioblastoma business and advance our proprietary cancer therapy to commercialize indications beyond GBM," said Bill Doyle, executive chairman of NovoCure.

Concurrently, NovoCure said Gert Lennart Perlhagen is retiring as a board member after 15 years of service.

St. Helier, Jersey-based NovoCure is developing treatments for solid tumors.